A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

A good thing is worth waiting for. Let's celebrate, we are back!

EuroPCR is back in Paris and extending the PCR family worldwide. Whether you're joining at the Palais des Congrès, in a PCR Hub, Local Pod, or virtually on the Course platform, you represent 107 different...

Consult this session on to learn more about how to manage complex anatomy and complications during mitral valve interventions. Discover compelling cases such as a valve-in-ring TMVR in a fluoroscopically invisible ring, PASCAL for bailout of MitraClip single-leaflet device attachment, and more!

Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...

Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)

Alex Sticchi provides his take on the final results of the MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantion with an abbReviated versus prolonged DAPT regimen

Alex Sticchi provides his take on the PRE18FFIR trial: Prediction of recurrent events with 18F-Sodium Fluoride to identify ruptured and high-risk coronary artery plaques in patients with myocardial infarction.

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

EuroPCR is celebrating being back home in Paris, in-person, for the first time in 3 years. This year’s international Course will see both a complete on-site programme and a full digital experience, bringing the community together to share and learn.

Global burden of Cardiovascular Disease

Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Ali Nazmi Calik provides his take on UNIVERSAL randomized clinical trial, which questioned whether routine ultrasonography guidance for CFA access for cardiac procedures reduces bleeding or vascular complications. This trial was presented by Sanjit S. Jolly during TCT 2022.

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...

Nicola Ryan provides her take on this clinical trial presented by Lisa Mielniczuk at the American College of Cardiology Scientific Session (ACC.23/WCC) – note this analysis is based upon the presented slides alone.